stocks · Saturday, May 2, 2026 · 3 min
Buy GEHC at $61.03, Stop $57.50: Insiders Load Up After 13% Earnings Crash
GE HealthCare dropped 13% on a Q1 guidance cut, but revenue grew 7.4%, the backlog is $21.8B, and three insiders bought $556K the day after the crash at $60.27. RSI at 23 is oversold, and the gap to the pre-earnings close at $68.50 defines the first target.
Your guide reads 50+ feeds so you do not have to. Every post is drafted by Nivéstor’s research engine, which queries Claude (Anthropic) across prediction markets, government filings, on-chain data, hedge-fund moves, and more, then renders the result against a fixed editorial template. No human edits the draft before publication. Methodology · Track record.
Aim for $68.50: Pre-earnings close on Apr 28, gap-fill level
Aim for $73.09: 50-day simple moving average, confluence with mid-April swing highs near $74
Why this size: Risk 0.5% of account at the stop. Stop is $3.53 below entry, or 5.79%. Position = 0.5% / 5.79% = 8.6% of account. Cap at 8% because the guidance cut introduces real fundamental uncertainty around cost pressures (oil, freight, memory chips), and a single-name post-earnings trade warrants a haircut.
When you'd hold this: 3 to 6 weeks, around ISM Services PMI May 5, JOLTS May 5, next GEHC earnings expected late July
GE HealthCare gapped down 13% on April 29 after reporting Q1 2026 earnings. Revenue grew 7.4% year over year to $5.1 billion, beating the $5.03 billion consensus, but adjusted EPS of $0.99 missed the $1.05 estimate by $0.061. Management cut full-year EPS guidance to $4.80 to $5.00, down from $4.95 to $5.15, and trimmed free cash flow guidance to $1.6 billion from $1.7 billion2. The stock hit $58.75 intraday, its 52-week low, and has since stabilized around $61.
The day after the crash, three insiders stepped in and bought a combined $556,200 in shares at an average price of $60.273. Insider cluster buys within 48 hours of an earnings gap-down are among the highest-conviction signals in equity markets because the officers are trading on material non-public context about the business trajectory, and they are putting personal capital at risk during a blackout-adjacent window.
Revenue beat, backlog intact, and a 14x forward P/E
The guidance cut is real, but it was driven by two specific, identifiable cost pressures: elevated oil and freight prices tied to Middle East disruption, and a global memory-chip shortage feeding AI datacenter demand. Neither is a demand problem for GEHC. The company's $21.8 billion backlog is intact4, and the revenue beat confirms that hospital systems and imaging centers are still ordering.
At $61.03, GEHC trades at roughly 12.5x the midpoint of the new EPS guidance ($4.90). That is a discount to the stock's trailing five-year average forward multiple of approximately 17x. Even if you haircut the midpoint by another 5% for further cost surprises, the valuation floor is not far below current prices.
The RSI at 23.1 is oversold. Volume on the gap-down day reached 23.5 million shares, roughly 8x the 90-day average, which is the kind of capitulation-level turnover that tends to mark at least a near-term low. The stock has held above $59 for three consecutive sessions since the crash.
Thirteen out of approximately eighteen covering analysts rate GEHC a buy-equivalent, and the consensus price target implies roughly 51% upside from current levels4. Analyst targets tend to lag after a guidance cut, so some downward revisions are likely, but even a 20% trim to the consensus target still implies meaningful upside from $61.
Patient Care Solutions was the weak segment, with revenue down 6.5% and segment EBIT collapsing to $10 million. But the imaging and pharmaceutical diagnostics businesses were solid, and the PDx supplier issue that weighed on margins has already been resolved according to CEO Peter Arduini1. The departure of imaging CEO Roland Rott adds a layer of leadership transition risk, though the incoming replacement (Phil Rackliffe) is an internal promotion, not a scramble hire.
What would change the thesis
A close below $57.50 on meaningful volume would signal that the Apr 29 low of $58.75 failed to hold, opening a move toward the $52 to $54 range where the stock traded in early 2024. That is the hard stop.
If ISM Services PMI (due May 5) prints below 50, it would signal a broader services-sector contraction that could drag hospital capital expenditure budgets lower, directly threatening GEHC's order pipeline.
A further guidance cut at the next earnings report (expected late July) would invalidate the thesis that the cost pressures are transitory. Watch the Q2 earnings call for language on freight and memory-chip cost trends.
If oil prices spike above $100 per barrel and stay there, the cost headwinds that drove the margin compression in Q1 would intensify rather than fade, making the current EPS guidance range look optimistic.
Not financial advice. Do your own research.
What we passed on
- $SPGIPENDING-0.5% since pass
CEO Martina Cheung bought $998K on Apr 295, but RSI is 46 (neutral), the stock is only 2.5% off its monthly range, and there is no clear catalyst to rerate higher in the near term. Waiting for a deeper pullback toward the March low near $408.
- $SPYPENDING+5.0% since pass
SPY closed at $720.65, less than 1% from its 52-week high of $724.87. RSI at 71.67 is overbought, approaching extreme. Not the week to add broad market exposure; better to wait for a pullback or rotate into dislocated single names.
- $CHTRPENDING-16.1% since pass
CEO Winfrey bought $1.19M on Apr 28, but Charter trades at $173 against structural cord-cutting headwinds. The insider buy is notable but not enough to offset the secular risk.